If your drug company is on its death-bed, this is the man you want as your corporate doctor. He's Fred Hassan, the CEO of drug giant Schering-Plough. In the past 25 years, he has turned around his fair share of ailing pharmaceutical firms, including the recovery and subsequent 56 billion dollar sale of Pharmacia. He's so renowned within his industry that they coined a phrase for his brand of management: "The Fred Factor." Hassan tells The Boardroom's Maggie Lake how he is able to assess, diagnose and cure.
Schering-Plough may have lost billions of dollars in the fourth quarter from an acquisition, but its stock jumped Tuesday as the drugmaker's earnings without charges beat expectations.
As Schering-Plough unveils full-year financial results for 2007 tomorrow, CEO Fred Hassan is likely to be peppered with questions about how he managed a recently released study of embattled cholesterol drug, Vytorin.
THE TYPICAL FORTUNE 500 COMPANY rarely has trouble filling the job when a CEO retires (or gets fired). To wit: Less than two months after Carly Fiorina's ouster, Hewlett-Packard announced NCR CEO M...
Fred Hassan talks like a professional therapist. Not in a cooing, I-feel-your-pain, Oprah sort of way, but with a gentle authority that, no matter how harsh the pronouncement, is still soothing. Sc...
A tired product mix hamstrung by slow sales growth. A CEO who quits without warning. Repeated earnings disappointments. And a sprawling corporate empire with executives in four countries who speak ...
If your drug company is on its death-bed, this is the man you want as your corporate doctor. He's Fred Hassan, the CEO of drug giant Schering-Plough. In the past 25 years, he has turned around his fair share of ailing pharmaceutical firms, including the recovery and subsequent 56 billion dollar sale of Pharmacia. He's so renowned within his industry that they coined a phrase for his brand of management: "The Fred Factor." Hassan tells The Boardroom's Maggie Lake how he is able to assess, diagnose and cure.
Schering-Plough may have lost billions of dollars in the fourth quarter from an acquisition, but its stock jumped Tuesday as the drugmaker's earnings without charges beat expectations.
As Schering-Plough unveils full-year financial results for 2007 tomorrow, CEO Fred Hassan is likely to be peppered with questions about how he managed a recently released study of embattled cholesterol drug, Vytorin.
THE TYPICAL FORTUNE 500 COMPANY rarely has trouble filling the job when a CEO retires (or gets fired). To wit: Less than two months after Carly Fiorina's ouster, Hewlett-Packard announced NCR CEO M...
Fred Hassan talks like a professional therapist. Not in a cooing, I-feel-your-pain, Oprah sort of way, but with a gentle authority that, no matter how harsh the pronouncement, is still soothing. Sc...
A tired product mix hamstrung by slow sales growth. A CEO who quits without warning. Repeated earnings disappointments. And a sprawling corporate empire with executives in four countries who speak ...
The page you requested cannot be found. The page you are looking for might have been removed, had its name changed, or is temporarily unavailable.
Please try the following:
If you typed the page address in the Address bar, make sure that it is spelled correctly.
Open the edition.cnn.com home page and look for links to the information you want.
Use the navigation bar above to find the link you are looking for.
Click the Back button to try another link.
Enter a term in the search form below to look for information on CNN sites or the Internet.